Get the Stockscreener App
0.271
3.21%
-0.009
Pre-market:
.27
-0.001
-0.37%
Azitra Inc stock is traded at $0.271, with a volume of 441.34K.
It is down -3.21% in the last 24 hours and down -11.73% over the past month.
Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.
See More
Previous Close:
$0.28
Open:
$0.2725
24h Volume:
441.34K
Relative Volume:
0.34
Market Cap:
$4.47M
Revenue:
$1.27M
Net Income/Loss:
$-11.28M
P/E Ratio:
-0.0121
EPS:
-22.4496
Net Cash Flow:
$-10.46M
1W Performance:
-4.98%
1M Performance:
-11.73%
6M Performance:
-48.38%
1Y Performance:
+32.20%
1-Day Range:
$0.2613
$0.2755
1-Week Range:
$0.2613
$0.299
52-Week Range:
$0.0922
$12.00
Azitra Inc Stock (AZTR) Company Profile
Name
Azitra Inc
Sector
Industry
Phone
203 646 6446
Address
21 Business Park Drive, Branford
Compare AZTR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZTR
Azitra Inc
|
0.271 | 4.70M | 1.27M | -11.28M | -10.46M | -22.45 |
|
ONC
Beone Medicines Ltd Adr
|
246.68 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.09 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.30 | 40.37M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.39 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
77.49 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
Azitra Inc Stock (AZTR) Latest News
Revolutionary Skin Microbiome Treatment Could Help Cancer Patients Stay on Life-Saving Therapy - Stock Titan
FY2025 EPS Estimates for Azitra Lifted by Zacks Small Cap - Defense World
What is Zacks Small Cap’s Forecast for Azitra Q2 Earnings? - Defense World
AZTR: ATR-04 Trial to Dose 1st Patient Mid-2025 - MSN
Azitra (NYSEAMERICAN:AZTR) Trading Up 0.9% – Time to Buy? - Defense World
Azitra, Inc. to Present Abstract at American Society of Gene and Cell Therapy Highlighting Phase 1/2 Study Targeting Cancer Therapy-Associated Rash - Seeking Alpha
Azitra, Inc. Announces Q1 2025 Results and Provides Business Updates - Nasdaq
Azitra Advances Novel Skin Disease Treatments: Key Trial Results Expected in 2025 - Stock Titan
Stock Of Azitra Inc (AMEX: AZTR) Jumped By 6.67 Percent Over The Past Month, Is There Room For Upside? - Marketing Sentinel
Azitra Inc (AZTR)’s Day in Review: Closing at 0.30, Down by -6.51 - DWinneX
Azitra Inc (AZTR) Stock: Navigating Drops and Gains - investchronicle.com
Azitra Inc [AZTR] Investment Appeal on the Rise - knoxdaily.com
Azitra Inc (AMEX:AZTR) stock: You might be surprised - uspostnews.com
Stocks of Azitra Inc (AZTR) are poised to climb above their peers - Sete News
Azitra (AZTR) Secures Funding Through $20 Million Share Purchase Agreement - GuruFocus
What to expect from Azitra Inc’s (AZTR) current quarter earnings? - uspostnews.com
AZTR’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - investchronicle.com
Branford-based biopharma Azitra Inc. gains $20M in partnership deal with Alumni Capital - Hartford Business Journal
Azitra (AZTR) to Highlight Precision Dermatology Advances at Bru - GuruFocus
Market Momentum: Azitra Inc (AZTR) Registers a 3.73 Increase, Closing at 0.31 - DWinneX
Azitra, Inc. to Present ATR-04 Program Update at ASCO 2025 - The Victoria Advocate
Why Coursera Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving Premarket - Benzinga
Azitra enters share purchase agreement with Alumni Capital for up to $20M - MSN
Azitra secures funding deal for dermatology treatments By Investing.com - Investing.com India
Azitra secures funding deal for dermatology treatments - Investing.com
$20M Strategic Investment Accelerates Azitra's Breakthrough Treatments for 150,000 Rare Disease Patients - Stock Titan
Azitra (NYSEAMERICAN:AZTR) Trading Up 3.9% – Here’s Why - Defense World
Azitra Announces Proposed Public Offering of Common Stock (PR Newswire) - Aktiellt
Azitra, Inc. (NYSEAMERICAN:AZTR) Shares Acquired by Virtu Financial LLC - Defense World
Teacher Retirement System of Texas Makes New $236,000 Investment in Grail, Inc. (NASDAQ:GRAL) - Defense World
Azitra (AZTR) Expected to Announce Quarterly Earnings on Friday - Defense World
Azitra to Present at Microbiome Times Partnering Forum – Company Announcement - Financial Times
Azitra to Present at Microbiome Times Partnering Forum - PR Newswire
Microbiome Disease Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 140+ Companies and 180+ Therapies | DelveInsight - GlobeNewswire
AZTR: Netherton Topline Expected by Year-End - MSN
Azitra, Inc. (NYSEAMERICAN:AZTR) Short Interest Up 144.1% in February - Defense World
Azitra, Inc. Announces Full Year 2024 Financial Results and Provides Business Updates - Citizentribune
Azitra, Inc. Announces FY 2024 Financial Results and Business Updates - Defense World
Maxim Group cuts Azitra stock price target to $2 from $3, retains Buy rating - Investing.com
Maxim Group cuts Azitra stock price target to $2 from $3, retains Buy rating By Investing.com - Investing.com South Africa
Volcon, Inc. and GlucoTrack, Inc. See Massive Gains, While Omega Therapeutics and Universe Pharmaceuticals Struggle - HPBL
Azitra Inc Stock (AZTR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.95%
Cap:
|
Volume (24h):